Literature DB >> 12030893

Cardiomyopathy in congenital complete lipodystrophy.

S Bhayana1, V M Siu, G I Joubert, C L Clarson, H Cao, R A Hegele.   

Abstract

Molecular genetic studies have pointed to a relationship between congenital lipodystrophy syndromes and some cardiac disorders. For instance, mutations in LMNA cause either lipodystrophy or cardiomyopathy, indicating that different mutations in the same gene can produce these clinical syndromes. The present authors describe a 10-year-old female with Berardinelli-Seip congenital complete lipodystrophy (MIM 606158) caused by homozygosity for a frameshift mutation in BSCL2. In addition to the typical attributes of complete lipodystrophy, this subject had hypertrophic cardiomyopathy diagnosed in the first year of her life; its progress has been followed with non-invasive imaging. The mechanism underlying the hypertrophic cardiomyopathy in complete lipodystrophy is unclear. It may result from a direct effect of the mutant gene or it might be secondary to the effects of hyperinsulinemia on cardiac development. The variability of the associated cardiomyopathy in patients with complete generalized lipodystrophy may be caused by differential effects of mutations in the same gene or of mutations in different genes which underlie the lipodystrophy phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12030893     DOI: 10.1034/j.1399-0004.2002.610407.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  24 in total

1.  A Patient with Congenital Generalized Lipodystrophy Due To a Novel Mutation in BSCL2: Indications for Secondary Mitochondrial Dysfunction.

Authors:  Ellen H Jeninga; Monique de Vroede; Nicole Hamers; Johannes M P J Breur; Nanda M Verhoeven-Duif; Ruud Berger; Eric Kalkhoven
Journal:  JIMD Rep       Date:  2011-11-04

Review 2.  Genetics of Lipodystrophy.

Authors:  Marissa Lightbourne; Rebecca J Brown
Journal:  Endocrinol Metab Clin North Am       Date:  2017-02-22       Impact factor: 4.741

3.  Targeting ATGL to rescue BSCL2 lipodystrophy and its associated cardiomyopathy.

Authors:  Hongyi Zhou; Xinnuo Lei; Yun Yan; Todd Lydic; Jie Li; Neal L Weintraub; Huabo Su; Weiqin Chen
Journal:  JCI Insight       Date:  2019-06-11

4.  Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy.

Authors:  Robert A Hegele; Henian Cao; Dora M Liu; Gary A Costain; Valentine Charlton-Menys; N Wilson Rodger; Paul N Durrington
Journal:  Am J Hum Genet       Date:  2006-06-05       Impact factor: 11.025

5.  Novel subtype of congenital generalized lipodystrophy associated with muscular weakness and cervical spine instability.

Authors:  Vinaya Simha; Anil K Agarwal; Patricia A Aronin; Susan T Iannaccone; Abhimanyu Garg
Journal:  Am J Med Genet A       Date:  2008-09-15       Impact factor: 2.802

6.  Berardinelli-Seip syndrome: highlight of treatment challenge.

Authors:  Nélia Ferraria; Cristina Pedrosa; Daniela Amaral; Lurdes Lopes
Journal:  BMJ Case Rep       Date:  2013-01-28

7.  Energy balance in congenital generalized lipodystrophy type I.

Authors:  Sasha Taleban; Heather T Carew; Helén L Dichek; Samir S Deeb; David Hollenback; David S Weigle; David E Cummings; John D Brunzell
Journal:  Metabolism       Date:  2008-08       Impact factor: 8.694

Review 8.  Severe insulin resistance syndromes.

Authors:  Angeliki M Angelidi; Andreas Filippaios; Christos S Mantzoros
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

Review 9.  Adiponectin, Leptin and Cardiovascular Disorders.

Authors:  Shangang Zhao; Christine M Kusminski; Philipp E Scherer
Journal:  Circ Res       Date:  2021-01-07       Impact factor: 17.367

Review 10.  Clinical Features and Management of Non-HIV-Related Lipodystrophy in Children: A Systematic Review.

Authors:  Nidhi Gupta; Noor Asi; Wigdan Farah; Jehad Almasri; Patricia Barrionuevo; Mouaz Alsawas; Zhen Wang; Morey W Haymond; Rebecca J Brown; M Hassan Murad
Journal:  J Clin Endocrinol Metab       Date:  2017-02-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.